Učitavanje...
Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors
The treatment landscape has changed since the immune checkpoint inhibitors were approved in the treatment of non-small cell lung cancer (NSCLC). Although the promising clinical benefit from programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors was observed in the second or subsequent...
Spremljeno u:
| Izdano u: | J Thorac Dis |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5994489/ https://ncbi.nlm.nih.gov/pubmed/29951304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.04.99 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|